NasdaqGS:INCYBiotechs
Incyte (INCY) Stock May Be 33% Overvalued After Opzelura EU Win
Incyte stock has delivered a strong 82.6% return over the past three years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium. With the valuation checks leaning cautious after this run, the recent news driven optimism around Opzelura and other pipeline assets meets a more conservative read from the models.
Over the last three years Incyte has returned 82.6%, which puts more pressure on the current share...